Clinical Trial Update: Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer

View source ↗

Summary

This completed study evaluates the use of the PET tracer Fluorine-18-α-methyltyrosine (18F-FMT) PET to assess therapy response in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Fluorine-18-α-Methyltyrosine (18F-FMT) PET tracer (Fluorine-18-labeled α-methyltyrosine)

Snippet

Sponsor: Gunma University | Conditions: Non-Small Cell Lung Cancer | Status: COMPLETED